JP4580364B2 - 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 - Google Patents
双極性障害を処置するための医薬を得るためのアゴメラチンの使用 Download PDFInfo
- Publication number
- JP4580364B2 JP4580364B2 JP2006116294A JP2006116294A JP4580364B2 JP 4580364 B2 JP4580364 B2 JP 4580364B2 JP 2006116294 A JP2006116294 A JP 2006116294A JP 2006116294 A JP2006116294 A JP 2006116294A JP 4580364 B2 JP4580364 B2 JP 4580364B2
- Authority
- JP
- Japan
- Prior art keywords
- bipolar disorder
- agomelatine
- type
- agomelatin
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
・ 希釈剤: ラクトース、デキストロース、スクロース、マンニトール、ソルビトール、セルロース、グリセロール;
・ 滑沢剤: シリカ、タルク、ステアリン酸並びにそのマグネシウム及びカルシウム塩、ポリエチレングリコール;
・ 結合剤: ケイ酸アルミニウム及びマグネシウム、デンプン、ゼラチン、トラガカントゴム、メチルセルロース、カルボキシメチルセルロースナトリウム、及びポリビニルピロリドン;
・ 崩壊剤: 寒天、アルギン酸及びそのナトリウム塩、発泡性混合物。
各錠剤が25mgの活性成分を含んでいる錠剤1000個を調製するための処方
N−[2−(7−メトキシ−1−ナフチル)エチル]アセトアミド.....25g
ラクトース一水和物...............................................62g
ステアリン酸マグネシウム...........................................1.3g
ポビドン...........................................................9g
無水コロイドシリカ.................................................0.3g
グリコール酸ナトリウムセルロース.................................30g
ステアリン酸.......................................................2.6g
この試験は、双極性障害I型に罹患している21人の患者で実施し、リチウム(n=14)又はバルプロエート(n=7)で、少なくとも6ヶ月間処置した。アゴメラチン(25mg/日)で6週間処置を行った。これらの患者のうち19人の患者には、6週間を超えて急性期処置を継続して行い、11人には、最長で1年間継続して処置を行った。得られた結果は、処置に対して患者の81%が良好に反応したことを示した。約50%は、ちょうど1週間の処置の最後までに良好に反応していた。6週間の処置を行った後、わずかに3例の躁病又は軽躁病の症状が観察された。これは、気分安定薬で見られる症状と完全に一致するレベルであった。このことは、双極性障害I型の患者におけるアゴメラチンの良好な作用は、長期間にわたる処置であっても、躁病及び/又は軽躁病の症状の発現の増大とは関係ないことを明瞭に示している。
Claims (2)
- アゴメラチン、即ち、N−[2−(7−メトキシ−1−ナフチル)エチル]アセトアミド、並びにその水和物、結晶形及び製薬上許容される酸又は塩基との付加塩を含む、双極性障害I型を処置するための医薬。
- アゴメラチン、又はその水和物、結晶形及び製薬上許容される酸若しくは塩基との付加塩の1種類を、単独で含んでいるか、あるいは1種類以上の製薬上許容される賦形剤と組み合わせて含んでいる、双極性障害I型を処置するための医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0503937A FR2884714B1 (fr) | 2005-04-20 | 2005-04-20 | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010177003A Division JP5341037B2 (ja) | 2005-04-20 | 2010-08-06 | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006316056A JP2006316056A (ja) | 2006-11-24 |
JP4580364B2 true JP4580364B2 (ja) | 2010-11-10 |
Family
ID=35311309
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006116294A Expired - Fee Related JP4580364B2 (ja) | 2005-04-20 | 2006-04-20 | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 |
JP2010177003A Expired - Fee Related JP5341037B2 (ja) | 2005-04-20 | 2010-08-06 | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010177003A Expired - Fee Related JP5341037B2 (ja) | 2005-04-20 | 2010-08-06 | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 |
Country Status (41)
Country | Link |
---|---|
US (1) | US7947743B2 (ja) |
EP (1) | EP1714647B1 (ja) |
JP (2) | JP4580364B2 (ja) |
KR (2) | KR100835451B1 (ja) |
CN (2) | CN102038669A (ja) |
AP (1) | AP2656A (ja) |
AR (1) | AR057277A1 (ja) |
AT (1) | ATE491443T1 (ja) |
AU (1) | AU2006201655B2 (ja) |
BR (1) | BRPI0601285A8 (ja) |
CA (1) | CA2544136C (ja) |
CR (1) | CR9426A (ja) |
CY (1) | CY1111257T1 (ja) |
DE (1) | DE602006018822D1 (ja) |
DK (1) | DK1714647T3 (ja) |
EA (1) | EA013462B1 (ja) |
ES (1) | ES2357901T3 (ja) |
FR (1) | FR2884714B1 (ja) |
GE (1) | GEP20094651B (ja) |
GT (1) | GT200600141A (ja) |
HK (1) | HK1093906A1 (ja) |
HR (1) | HRP20110083T1 (ja) |
IL (1) | IL186373A (ja) |
JO (1) | JO2666B1 (ja) |
MA (1) | MA28266A1 (ja) |
ME (1) | ME01951B (ja) |
MY (1) | MY143171A (ja) |
NO (1) | NO336010B1 (ja) |
NZ (1) | NZ546630A (ja) |
PE (1) | PE20061337A1 (ja) |
PL (1) | PL1714647T3 (ja) |
PT (1) | PT1714647E (ja) |
RS (1) | RS51659B (ja) |
SG (1) | SG126868A1 (ja) |
SI (1) | SI1714647T1 (ja) |
TN (1) | TNSN07364A1 (ja) |
TW (2) | TW200940049A (ja) |
UA (1) | UA83681C2 (ja) |
UY (1) | UY29470A1 (ja) |
WO (1) | WO2006111653A1 (ja) |
ZA (1) | ZA200603160B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2890563B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent |
AU2008247805A1 (en) * | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Naphthyl(ethyl) acetamides |
FR2978916B1 (fr) * | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
EP2856934A1 (en) * | 2013-10-04 | 2015-04-08 | Les Laboratoires Servier | Biomarkers for the prediction of long term remission in depression |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5585118A (en) * | 1995-06-02 | 1996-12-17 | Brigham And Women's Hospital | Choline in the treatment of bipolar disorder |
RS50680B (sr) * | 2001-02-27 | 2010-06-30 | Ortho-Mcneil Pharmaceutical Inc. | Karbamatna jedinjenja za upotrebu u sprečavanju i lečenju bipolarnih poremećaja |
FR2834890B1 (fr) * | 2002-01-23 | 2004-02-27 | Servier Lab | Composition pharmaceutique orodispersible d'agomelatine |
AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
JP2007517040A (ja) * | 2003-12-24 | 2007-06-28 | セプレイコー インコーポレイテッド | 睡眠の質を改善するためのメラトニン併用療法 |
-
2005
- 2005-04-20 FR FR0503937A patent/FR2884714B1/fr not_active Expired - Fee Related
- 2005-06-01 US US11/142,612 patent/US7947743B2/en not_active Expired - Fee Related
-
2006
- 2006-04-04 JO JO200690A patent/JO2666B1/en active
- 2006-04-04 PE PE2006000362A patent/PE20061337A1/es not_active Application Discontinuation
- 2006-04-07 GT GT200600141A patent/GT200600141A/es unknown
- 2006-04-07 UY UY29470A patent/UY29470A1/es not_active Application Discontinuation
- 2006-04-11 SG SG200602393A patent/SG126868A1/en unknown
- 2006-04-11 UA UAA200604022A patent/UA83681C2/uk unknown
- 2006-04-17 MA MA28940A patent/MA28266A1/fr unknown
- 2006-04-18 NO NO20061705A patent/NO336010B1/no not_active IP Right Cessation
- 2006-04-19 AR ARP060101537A patent/AR057277A1/es not_active Application Discontinuation
- 2006-04-19 MY MYPI20061783A patent/MY143171A/en unknown
- 2006-04-19 RS RS20110110A patent/RS51659B/en unknown
- 2006-04-19 PL PL06290636T patent/PL1714647T3/pl unknown
- 2006-04-19 PT PT06290636T patent/PT1714647E/pt unknown
- 2006-04-19 GE GEAP20069356A patent/GEP20094651B/en unknown
- 2006-04-19 ES ES06290636T patent/ES2357901T3/es active Active
- 2006-04-19 KR KR1020060035392A patent/KR100835451B1/ko not_active IP Right Cessation
- 2006-04-19 DK DK06290636.7T patent/DK1714647T3/da active
- 2006-04-19 AP AP2007004212A patent/AP2656A/xx active
- 2006-04-19 EA EA200600600A patent/EA013462B1/ru not_active IP Right Cessation
- 2006-04-19 AT AT06290636T patent/ATE491443T1/de active
- 2006-04-19 TW TW098118938A patent/TW200940049A/zh unknown
- 2006-04-19 SI SI200630921T patent/SI1714647T1/sl unknown
- 2006-04-19 ME MEP-2011-231A patent/ME01951B/me unknown
- 2006-04-19 NZ NZ546630A patent/NZ546630A/en not_active IP Right Cessation
- 2006-04-19 WO PCT/FR2006/000859 patent/WO2006111653A1/fr active Application Filing
- 2006-04-19 TW TW095113952A patent/TWI318115B/zh not_active IP Right Cessation
- 2006-04-19 DE DE602006018822T patent/DE602006018822D1/de active Active
- 2006-04-19 EP EP06290636A patent/EP1714647B1/fr active Active
- 2006-04-20 JP JP2006116294A patent/JP4580364B2/ja not_active Expired - Fee Related
- 2006-04-20 AU AU2006201655A patent/AU2006201655B2/en not_active Ceased
- 2006-04-20 CN CN2010105781057A patent/CN102038669A/zh active Pending
- 2006-04-20 CA CA2544136A patent/CA2544136C/fr not_active Expired - Fee Related
- 2006-04-20 BR BRPI0601285A patent/BRPI0601285A8/pt not_active IP Right Cessation
- 2006-04-20 CN CN2006100764985A patent/CN1853619B/zh not_active Expired - Fee Related
- 2006-04-20 ZA ZA200603160A patent/ZA200603160B/en unknown
-
2007
- 2007-01-10 HK HK07100339.3A patent/HK1093906A1/xx not_active IP Right Cessation
- 2007-09-26 TN TNP2007000364A patent/TNSN07364A1/en unknown
- 2007-10-07 IL IL186373A patent/IL186373A/en not_active IP Right Cessation
- 2007-10-08 CR CR9426A patent/CR9426A/es not_active Application Discontinuation
-
2008
- 2008-02-29 KR KR1020080018845A patent/KR20080028389A/ko not_active Application Discontinuation
-
2010
- 2010-08-06 JP JP2010177003A patent/JP5341037B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-02 HR HR20110083T patent/HRP20110083T1/hr unknown
- 2011-02-23 CY CY20111100222T patent/CY1111257T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007077148A (ja) | うつ病患者における睡眠障害の処置を目的とした医薬品を得るためのアゴメラチンの使用 | |
JP4880031B2 (ja) | 全般性不安障害の処置に用いる医薬を製造するためのアゴメラチンの使用 | |
JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
JP5634529B2 (ja) | 強迫性障害(ocd)処置用の薬剤の製造のためのアゴメラチンの使用 | |
JP5395998B2 (ja) | アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物 | |
KR20110086673A (ko) | 스미스-마제니스 증후군 치료용 약제 제조시 아고멜라틴의 용도 | |
US7902180B2 (en) | Association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it | |
MXPA06004292A (en) | Use of agomelatin in the manufacture of a medicament for the treatment of bipolar disorders | |
JP2009013074A (ja) | 全般性不安障害の処置を目的とする医薬を得るためのアゴメラチンの使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100331 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100806 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100827 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4580364 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |